HCRT

Hypocretin/Orexin

Score: 0.549 Price: $0.55 Medium Druggability Status: active Wiki: HCRT

🧠 Neurodegeneration

HYPOTHESES

3

PAPERS

31

KG EDGES

144

DEBATES

0

3D Protein Structure

🔮 HCRT — AlphaFold O43612 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.46

Clinical Stage

Approved

Target Class

Ligand

Safety

0.60

Druggability Analysis

Drug Development1.00

Structural Tractability0.30

Target Class0.50

Safety Profile0.60

Key Metrics

PDB Structures:

0

Known Drugs:

3

Approved:

3

In Clinical Trials:

0

Drug Pipeline (3 compounds)

3 Approved

Therapeutic Areas:

Oncology Immunology Ophthalmology

Druggability Rationale: This ligand has moderate druggability. Soluble ligand traps or receptor-level intervention may be more tractable than direct small molecule antagonism. AlphaFold predicted structure available for computational screening. 3 approved drug(s) validate this target pharmacologically.

Mechanism: Peptide hormone replacement or stabilization approaches

Drug Pipeline (3 compounds)

3 Approved

Known Drugs:

suvorexant (approved) — insomnia

lemborexant (approved) — insomnia

daridorexant (approved) — insomnia

Structural Data:

PDB —AlphaFold ✓Cryo-EM ✓

UniProt: O43612

Binding Pocket Analysis:

Receptor interaction surface

🔮 Predicted Protein Structure (AlphaFold)

🔮 HCRT — AlphaFold O43612 Click to expand interactive 3D viewer

AI-predicted structure from AlphaFold EBI | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity is assessed at the receptor level. Ligand traps may cross-react with related growth factors sharing receptor subunits.

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for O43612

View AlphaFold Structure

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

8

Completed

0

Total Enrollment

655

By Phase

PHASE2: 4 · PHASE4: 4

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease Recruiting

PHASE4 NCT07384429 n=44

Parkinson's Disease, Insomnia, Motor Disorder

Interventions: Lemborexant, placebo

Sponsor: YangPan | Started: 2026-03-19

Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease Recruiting

PHASE4 NCT05924425 n=62

Alzheimer Disease, Insomnia Disorder, Sleep

Interventions: Daridorexant 50 mg, Placebo, Polysomnography

Sponsor: University Hospital, Montpellier | Started: 2024-03-13

Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes Recruiting

PHASE4 NCT05593653 n=61

Insomnia, Diabetes, Menopause

Interventions: Suvorexant, Placebo

Sponsor: Brigham and Women's Hospital | Started: 2023-01-06

Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial Recruiting

PHASE4 NCT06093126 n=1

Insomnia, Dementia, Frontotemporal Dementia

Interventions: Lemborexant 5 MG

Sponsor: Nova Scotia Health Authority | Started: 2023-12-11

DORA and LP in Alzheimer's Disease Biomarkers Recruiting

PHASE2 NCT06274528 n=201

Alzheimer Disease

Interventions: Lemborexant 10 mg, Lemborexant 20mg, Placebo

Sponsor: Washington University School of Medicine | Started: 2024-03-11

Daridorexant for Alzheimer Disease Prevention Recruiting

PHASE2 NCT07213349 n=240

Alzheimer Disease (AD)

Interventions: Daridorexant 50 mg, Placebo

Sponsor: Douglas Mental Health University Institute | Started: 2025-10-14

A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia. Recruiting

PHASE2 NCT06823752 n=20

Insomnia

Interventions: Lemborexant 10 MG, Placebo

Sponsor: Woolcock Institute of Medical Research | Started: 2025-05-13

Trial of Suvorexant for Sleep in Children With Autism Recruiting

PHASE2 NCT05546554 n=26

Autism, Autism Spectrum Disorder

Interventions: Suvorexant, Placebo

Sponsor: Stanford University | Started: 2023-08-09

Linked Hypotheses (1)

Hypocretin-Neurogenesis Coupling Therapy0.452

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

activates (1)

HCRT → HCRTR1

associated with (2)

HCRT → neurodegeneration

HCRT → HCRTR1

co discussed (11)

HCRT → CACNA1G

HCRT → ADORA2A

HCRT → ADRA2A

...and 6 more

implicated in (1)

HCRT → neurodegeneration

interacts with (2)

HCRT → HCRTR2

HCRT → HCRTR1

participates in (1)

HCRT → Hypocretin/orexin wakefulness signaling

regulates (2)

HCRT → HCRTR1

Debate History (0)

No debates yet